K-924 Phase III Long Term Study

Phase 3

Completed

• Conditions: Hypercholesterolemia
• Interventions: Drug: K-924 LD; Drug: K-924 HD

• Registration Number: NCT04289662
• Lead Sponsor: Kowa Company, Ltd.

Brief Summary

A Multicenter, Open-label Study to Evaluate 52 weeks long term Efficacy and Safety of K-924 in Patients with hypercholesterolemia who were treated with pitavastatin 2 mg or 4 mg.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2020-02-26
• Study First Submitted QC: 2020-02-27
• Study First Posted: 2020-02-28
• Study Start: 2020-03-23
• Primary Completion: 2021-08-07
• Study Completion: 2021-08-07
• Status Verified: 2023-11
• Last Update Submitted: 2023-11-26
• Last Update Posted: 2023-11-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 110

Inclusion Criteria

1. Patients with hypercholesterolemia had to be age 20 years or older at written informed consent (ICF)

2. Patients who have been on a diet and / or exercise regimen more than 4 weeks before the screening

3. Patients who have been receiving pitavastatin calcium 2 mg / day or pitavastatin calcium 4 mg / day at least 4 weeks prior to the screening

4. Those whose LDL-C (Friedewald formula) at the screening any of the following in the category classification based on Japan Atherosclerosis Society guidelines for prevention Atherosclerotic Cardiovascular Disease 2017

   • Low risk of primary prevention : LDL-C => 160 mg/dL
   • Medium risk of primary prevention : LDL-C => 140 mg/dL
   • High risk of primary prevention : LDL-C => 120 mg/dL
   • Secondary prevention patients with a history of coronary artery disease : LDL-C => 100 mg/dL
   • Secondary prevention patients with familial hypercholesterolemia or acute coronary syndrome, or diabetes with other high-risk conditions : LDL-C => 70 mg/dL

Exclusion Criteria

1. Patients with a history of myopathy or rhabdomyolysis due to pitavastatin or ezetimibe
2. Patients with a history of hypersensitivity due to pitavastatin or ezetimibe
3. Patients with severe liver damage (Child Pugh Class B or higher) or biliary obstruction
4. Pregnant women, lactating women, women planning to become pregnant or lactating during the study period, or pregnant women who do not use specific contraceptive methods
5. Patients whose CK is 3 times or more of the upper limit of the reference value at screening
6. Patients whose AST and ALT is 2 times or more of the upper limit of the reference value at screening
7. Patients wiht type 1 diabetes or uncontrolled type 2 diabetes as defined HbA1c 8 % or more at screening
8. Patients with uncontrolled hypertension as defined systolic blood pressure of 160 mmHg or more or diastolic blood pressure of 100 mmHg or more at screening
9. Patients with eGFR of less than 30 mL / min / 1.73 m² at screening or dialysis
10. Patients with heart failure class III or higher according to NYHA cardiac function classification
11. Patients with uncontrolled arrhythmia
12. Patients with uncontrolled metabolic endocrine disease
13. Patients with malignant tumors or who are judged to have a high possibility of relapse
14. Patients who developed acute coronary syndrome or stroke within 12 months before obtaining consent
15. Patients who have collected 200 mL or more within 4 weeks before screening, 400 mL or more of blood within 12 weeks for males or 16 weeks for females, or within 2 weeks for (Plasma component / platelet component)
16. Persons with a history of severe drug allergy (anaphylactic shock, etc.)
17. Patients who need contraindicated drugs during the study period after obtaining consent
18. Patients with TG of 400 mg / dL or more at screening
19. Patients who have LDL apheresis
20. Patients with malabsorption or history, or who have undergone gastrointestinal surgery (excluding appendectomy, hernia treatment, etc.) that may affect absorption.
21. Patients with Alcohol or drug addiction
22. Patients who participate in other clinical trials within 16 weeks prior to study drug administration and who are administered non-placebo investigational drugs, or who participate in other clinical trials concurrently with this study
23. Patients who have received K-924
24. Patients who judged to be inappropriate by the Investigator or Investigator

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
K-924 LD	K-924 LD	K-924 LD once daily
K-924 HD	K-924 HD	K-924 HD once daily

Primary Outcome Measures

Name	Time	Method
Efficacy: % change from baseline in LDL-C (Friedewald formula) (mg/dL)	Week 52

Secondary Outcome Measures

Name	Time	Method
Efficacy: % change or change from baseline in LDL-C (mg/dL)	From baseline upto week 52
Efficacy: % change or change from baseline in non-HDL-C (mg/dL)	From baseline upto week 52
Efficacy: % change or change from baseline in HDL-C (mg/dL)	From baseline upto week 52
Efficacy: % change or change from baseline in TG (mg/dL)	From baseline upto week 52
Efficacy: % change or change from baseline in Total Cholesterol (mg/dL)	From baseline upto week 52

Trial Locations

Locations (13)

Chubu Rosai Hospital; 🇯🇵 Aichi, Japan

Daido Clinic; 🇯🇵 Aichi, Japan

Nippon Kokan Fukuyama Hospital; 🇯🇵 Hiroshima, Japan

Nakamura Cardiovascular Clinic; 🇯🇵 Fukuoka, Japan

Hasegawa Medicine Clinic; 🇯🇵 Hokkaido, Japan

Miyanomori Memorial Hospital; 🇯🇵 Hokkaido, Japan

Yuri Ono Clinic; 🇯🇵 Hokkaido, Japan

Ota General Hospital; 🇯🇵 Kanagawa, Japan

Suwa Red Cross Hospital; 🇯🇵 Nagano, Japan

Shiraiwa medical clinic; 🇯🇵 Osaka, Japan

Minamino Cardiovascular Hospital; 🇯🇵 Tokyo, Japan

Tokyo Shinagawa Hospital; 🇯🇵 Tokyo, Japan

Tokyo-Eki Center-building Clinic; 🇯🇵 Tokyo, Japan